

Cech et al.
Application No.: 09/843,676
Page 2

PATENT

24. A pharmaceutical composition comprising the polypeptide of claim 21 and a pharmaceutically acceptable carrier.

25. An immunogenic composition comprising the polypeptide of claim 21 and an adjuvant.

26. The composition of claim 25, wherein the adjuvant is selected from the group consisting of Freund's adjuvant, a mineral gel, aluminum hydroxide, lysolecithin, pluronic polyol, a polyanion, a peptide, an oil emulsion, keyhole limpet hemocyanin (KLH), dinitrophenol (DNP), Bacillus Calmette-Guerin, and Corynebacterium parvum.

27. A method for eliciting an immune response to telomerase reverse transcriptase protein in a subject, comprising administering to the subject the polypeptide of claim 21.

28. The method of claim 27, further comprising assessing whether telomerase-specific antibody is produced as a result of the administration.

29. An immunogenic composition comprising a polypeptide consisting essentially of 5 to 10 consecutive amino acids of the sequence provided in SEQ. ID NO:225, and an adjuvant.

30. The composition of claim 29, wherein the adjuvant is selected from the group consisting of Freund's adjuvant, a mineral gel, aluminum hydroxide, lysolecithin, pluronic polyol, a polyanion, a peptide, an oil emulsion, keyhole limpet hemocyanin (KLH), dinitrophenol (DNP), Bacillus Calmette-Guerin, and Corynebacterium parvum.

31. A method for eliciting an immune response to telomerase reverse transcriptase protein in a subject, comprising administering to the subject a polypeptide consisting essentially of 5 to 10 consecutive amino acids of the sequence provided in SEQ. ID NO:225.

32. The method of claim 31, further comprising assessing whether telomerase-specific antibody is produced as a result of the administration. --